XML 99 R68.htm IDEA: XBRL DOCUMENT
v3.25.1

License, Acquisition, Research Collaboration and Sponsored Research Agreements - Additional Information (Details) |  |  |  |  |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended | 37 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 21, 2024 USD ($) | Apr. 19, 2024 USD ($) | Apr. 13, 2024 USD ($) | Dec. 03, 2021 USD ($) IntegerItem | Oct. 04, 2021 USD ($) | Jul. 16, 2021 USD ($) | Jan. 25, 2021 USD ($) | Aug. 06, 2020 USD ($) | May 28, 2020 USD ($) IntegerItem | Apr. 23, 2020 USD ($) | Nov. 30, 2020 USD ($) shares | Dec. 31, 2024 USD ($) | Sep. 30, 2024 USD ($) | Mar. 31, 2023 USD ($) | Jun. 30, 2022 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2024 USD ($) | Nov. 07, 2023 shares | Dec. 31, 2022 shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 74,091,000 | $ 53,130,000 |  |  |
Converted shares into common stock | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,559,600 | 13,559,600
Stelios Therapeutics Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development milestone paid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,000,000 |  |  |  |
Asset acquisition date of acquisition |  |  |  |  |  | Jul. 16, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset acquisition percentage of outstanding stock acquisition |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment to selling shareholders |  |  |  |  |  |  |  |  |  |  |  | $ 6,000,000 |  |  |  |  |  |  |  |
Milestone Received |  |  |  |  |  |  |  |  |  |  |  | $ 1,300,000 |  |  |  | $ 1,300,000 |  | $ 1,300,000 |  |
Series A Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Converted shares into common stock | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,070,027 | 8,070,027
Maximum | Stelios Therapeutics Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment to selling shareholders |  |  |  |  |  | $ 12,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adverum License Agreement | Adverum Biotechnologies Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
One-time up-front non-refundable fee paid |  |  |  |  |  |  | $ 7,500,000 |  |  |  |  |  |  | $ 7,500,000 |  |  |  |  |  |
Development milestone paid |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,500,000 |  |  |  |  |  |
Royalty payments description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement). |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |
License agreement termination notice period |  |  |  |  |  |  | 120 days |  |  |  |  |  |  |  |  |  |  |  |  |
Adverum License Agreement | Adverum Biotechnologies Inc | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and regulatory milestones due |  |  |  |  |  |  | $ 17,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Commercialization milestones due |  |  |  |  |  |  | $ 49,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Cornell License Agreements | Cornell University |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 700,000 |  |  |  |
License agreement termination notice period |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |
Number of license agreements | IntegerItem |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |
Upfront payment in cash |  |  |  |  |  |  |  |  | $ 300,000 |  |  |  |  |  |  |  |  |  |  |
Notes issued |  |  |  |  |  |  |  |  | 1,300,000 |  |  |  |  |  |  |  |  |  |  |
Notes with outstanding principal exchanged |  |  |  |  |  |  |  |  |  |  | $ 1,300,000 |  |  |  |  |  |  |  |  |
Cornell License Agreements | Cornell University | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Converted shares into common stock | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 126,258 |
Cornell License Agreements | Cornell University | Series A Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued on debt exchanged | shares |  |  |  |  |  |  |  |  |  |  | 1,337,610 |  |  |  |  |  |  |  |  |
Cornell First License Agreements | Cornell University | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Specific clinical and regulatory milestones due |  |  |  |  |  |  |  |  | 8,400,000 |  |  |  |  |  |  |  |  |  |  |
Cornell Second License Agreements | Cornell University |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical and regulatory milestone paid |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000 |  |  |  |  |
Cornell Second License Agreements | Cornell University | Maximum | Two Portfolios |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Specific clinical and regulatory milestones due |  |  |  |  |  |  |  |  | 4,300,000 |  |  |  |  |  |  |  |  |  |  |
Cornell Second License Agreements | Cornell University | Maximum | Third Portfolio |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Specific clinical and regulatory milestones due |  |  |  |  |  |  |  |  | $ 600,000 |  |  |  |  |  |  |  |  |  |  |
Cornell Third License Agreements | Cornell University |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000 |  |  |
License agreement termination notice period | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fee and initial data transfer fee | $ 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual data transfer fee | 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cornell Third License Agreements | Cornell University | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual license maintenance fees | 2,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cornell Third License Agreements | Cornell University | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commercialization milestones due | 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual license maintenance fees | 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone to be paid | $ 2,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
First UCSD License Agreement | Stelios Therapeutics Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
One-time up-front non-refundable fee paid |  |  |  |  |  |  |  | $ 20,000 |  | $ 20,000 |  |  |  |  |  |  |  |  |  |
License agreement termination notice period |  |  |  |  |  |  |  |  |  | 60 days |  |  |  |  |  |  |  |  |  |
First UCSD License Agreement | Stelios Therapeutics Inc | Research and Development Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
One-time up-front non-refundable fees |  |  |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |
First UCSD License Agreement | Maximum | Stelios Therapeutics Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and commercialization milestones due |  |  |  |  |  |  |  |  |  | $ 4,800,000 |  |  |  |  |  |  |  |  |  |
Second UCSD License Agreement | Stelios Therapeutics Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement termination notice period |  |  |  |  |  |  |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |
Second UCSD License Agreement | Stelios Therapeutics Inc | Research and Development Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
One-time up-front non-refundable fees |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |  |  |
Second UCSD License Agreement | Maximum | Stelios Therapeutics Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and commercialization milestones due |  |  |  |  |  |  |  | $ 2,400,000 |  |  |  |  |  |  |  |  |  |  |  |
Third UCSD License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 700,000 |  |  |  |
Research agreements term |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research agreement termination notice period |  |  | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Costs incurred for research |  |  | $ 700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment to research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 600,000 |  |  |  |
Additional costs incurred for research |  |  | $ 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Third UCSD License Agreement | Stelios Therapeutics Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
One-time up-front non-refundable fee paid |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement termination notice period |  |  |  |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and commercialization milestones description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | the Company to pay aggregate development and commercialization milestones of up to $4.0 million, and low- to mid-single digit royalties based on aggregate net sales. |  |  |  |
Third UCSD License Agreement | Stelios Therapeutics Inc | Research and Development Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development milestone paid |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000 |  |  |  |  |  |  |
One-time up-front non-refundable fees |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Third UCSD License Agreement | Maximum | Stelios Therapeutics Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and commercialization milestones due |  |  |  |  | $ 4,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
UCSD Sponsored Research Agreements | Stelios Therapeutics Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 | 1,300,000 |  |  |
Number of research agreements | IntegerItem |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research agreements term |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research agreement termination notice period |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Costs incurred for research |  |  |  | $ 5,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment to research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 700,000 | 400,000 | $ 4,000,000 |  |
Amended First UCSD Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 600,000 |  |  |  |
Costs incurred for research |  | $ 700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment to research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 300,000 |  |  |  |
Research Collaboration Agreement | Weill Cornell Medical College |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 400,000 | 1,000,000 |  |  |
Payment to research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 300,000 | $ 2,100,000 |  |  |

X
- Definition aggregate development and commercialization milestones description. + References No definition available. + Details
Name: | lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription
Namespace Prefix: | lxeo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commercialization milestones due. + References No definition available. + Details
Name: | lxeo_CommercializationMilestonesDue
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development and commercialization milestones due. + References No definition available. + Details
Name: | lxeo_DevelopmentAndCommercializationMilestonesDue
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development and regulatory milestones due. + References No definition available. + Details
Name: | lxeo_DevelopmentAndRegulatoryMilestonesDue
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement termination notice period. + References No definition available. + Details
Name: | lxeo_LicenseAgreementTerminationNoticePeriod
Namespace Prefix: | lxeo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone received + References No definition available. + Details
Name: | lxeo_MilestoneReceived
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of license agreements. + References No definition available. + Details
Name: | lxeo_NumberOfLicenseAgreements
Namespace Prefix: | lxeo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of research agreements. + References No definition available. + Details
Name: | lxeo_NumberOfResearchAgreements
Namespace Prefix: | lxeo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition One time up front non refundable fees. + References No definition available. + Details
Name: | lxeo_OneTimeUpFrontNonRefundableFees
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment of annual data transfer fee. + References No definition available. + Details
Name: | lxeo_PaymentOfAnnualDataTransferFee
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment of annual license maintenance fees + References No definition available. + Details
Name: | lxeo_PaymentOfAnnualLicenseMaintenanceFees
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment Of Clinical And Regulatory Milestone. + References No definition available. + Details
Name: | lxeo_PaymentOfClinicalAndRegulatoryMilestone
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment of development milestone. + References No definition available. + Details
Name: | lxeo_PaymentOfDevelopmentMilestone
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment of license issue fee and initial data transfer fee + References No definition available. + Details
Name: | lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment of one time up front non refundable fee. + References No definition available. + Details
Name: | lxeo_PaymentOfOneTimeUpFrontNonRefundableFee
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment of regulatory milestones + References No definition available. + Details
Name: | lxeo_PaymentOfRegulatoryMilestones
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research agreement termination notice period. + References No definition available. + Details
Name: | lxeo_ResearchAgreementTerminationNoticePeriod
Namespace Prefix: | lxeo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research agreements term. + References No definition available. + Details
Name: | lxeo_ResearchAgreementsTerm
Namespace Prefix: | lxeo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and development Aarrangement, ontract to perform for others, dditional costs incurred. + References No definition available. + Details
Name: | lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Specific clinical and regulatory milestones due. + References No definition available. + Details
Name: | lxeo_SpecificClinicalAndRegulatoryMilestonesDue
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront cash payment. + References No definition available. + Details
Name: | lxeo_UpfrontCashPayment
Namespace Prefix: | lxeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 7 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-7 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 6 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-6 + Details
Name: | us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details
Name: | us-gaap_DebtConversionConvertedInstrumentSharesIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details
Name: | us-gaap_DebtConversionOriginalDebtAmount1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The fair value of notes issued in noncash investing and financing activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details
Name: | us-gaap_NotesIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of common shares issuable upon conversion of preferred stock. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockConvertibleSharesIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lxeo_SteliosTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lxeo_AdverumLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lxeo_AdverumBiotechnologiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lxeo_CornellUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lxeo_CornellFirstLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lxeo_CornellSecondLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_TwoPortfoliosMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_ThirdPortfolioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lxeo_FirstUcsdLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lxeo_UcsdSponsoredResearchAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lxeo_AmendedFirstUcsdAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lxeo_ResearchCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lxeo_WeillCornellMedicalCollegeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |